US$ 20.21
mounjaro tirzepatide approvazione italia (TIRZEPATIDE) INJECTION Obesità e diabete: via libera
Description
Headaches Headaches are particularly common in the first few weeks

Tirzepatide, developed by Eli Lilly, is a synthetic peptide that activates both GLP-1 and GIP receptors
The generic name for this medication is Zepbound

In weight loss studies, non-diabetic participants had similar outcomes between the 10mg and 15mg/weekly doses of tirzepatide

For drugs approaching LOE, the negotiation window may be short enough that the financial impact is limited, but the precedent effect on drug pricing during the last years of exclusivity is real
